The introduction of new GLP-1 receptor agonist drugs results in better treatment of diabetes and obesity, but also in a potential risk of inducing new adverse reactions that have not yet been properly described [9]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.